Page last updated: 2024-10-30

mesalamine and Myeloproliferative Disorders

mesalamine has been researched along with Myeloproliferative Disorders in 1 studies

Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.

Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.

Research Excerpts

ExcerptRelevanceReference
"No significant risk for other intestinal cancers was found, especially for small bowel carcinoma."1.43Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study. ( Charpentier, C; Cheddani, H; Dauchet, L; Dupas, JL; Fumery, M; Gower-Rousseau, C; Marie Bouvier, A; Pariente, B; Peyrin-Biroulet, L; Savoye, G, 2016)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cheddani, H1
Dauchet, L1
Fumery, M1
Charpentier, C1
Marie Bouvier, A1
Dupas, JL1
Pariente, B1
Peyrin-Biroulet, L1
Savoye, G1
Gower-Rousseau, C1

Other Studies

1 other study available for mesalamine and Myeloproliferative Disorders

ArticleYear
Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
    The American journal of gastroenterology, 2016, Volume: 111, Issue:10

    Topics: Adrenal Cortex Hormones; Age of Onset; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroi

2016